Vanguard Capital Management
PACB icon

Vanguard Capital Management’s Pacific Biosciences PACB Stock Holding History

Vanguard Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.5M Buy
13,397,934
+620,485
+5% +$902K ﹤0.01% 2379
2026
Q1 		$16.9M Buy
+12,777,449
New +$22.9M ﹤0.01% 2442

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management's PACB Position: Q2 2026 in Review

Vanguard Capital Management increased its Pacific Biosciences (PACB) stake by 4.9% in Q2 2026, buying an estimated $902K and bringing the position to 13,397,934 shares worth $22.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2379.

Vanguard Capital Management first reported a position in PACB in Q1 2026 and has held it in 2 quarters since. 220 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Vanguard Capital Management held 13,397,934 shares of Pacific Biosciences worth $22.5M as of Q2 2026.
  • Vanguard Capital Management bought 620,485 Pacific Biosciences shares in Q2 2026, an estimated $902K.
  • Pacific Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2379 holding.
  • Vanguard Capital Management first reported a position in Pacific Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 220 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.